Blood markers may forecast pregnancy risks in autoimmune disorder
NCT ID NCT02855047
First seen Nov 21, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study looked at 513 women with antiphospholipid syndrome starting a new pregnancy. Researchers measured two blood markers (PGF and sFlt1) before and after the first heparin injection to see if they could predict serious pregnancy complications like preeclampsia, placental abruption, or poor fetal growth. The goal was to improve monitoring and care, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémea
Nîmes, 30029, France
Conditions
Explore the condition pages connected to this study.